<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004147</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067379</org_study_id>
    <secondary_id>NABTT-9809</secondary_id>
    <secondary_id>JHOC-NABTT-9809</secondary_id>
    <nct_id>NCT00004147</nct_id>
  </id_info>
  <brief_title>COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors</brief_title>
  <official_title>A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Brain Tumor Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have&#xD;
      progressive or recurrent brain tumors following radiation therapy or chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose, dose limiting toxicity, and safety profile of oral&#xD;
           COL-3 alone or when combined with anticonvulsants known to be metabolized by CYP450 in&#xD;
           patients with progressive or recurrent high grade anaplastic astrocytoma, anaplastic&#xD;
           oligodendroglioma, or glioblastoma multiforme.&#xD;
&#xD;
        -  Define the pharmacokinetics and pharmacodynamics of COL-3 on this schedule and determine&#xD;
           the effects of hepatic enzyme inducing drugs, such as anticonvulsants, on the&#xD;
           pharmacokinetics.&#xD;
&#xD;
        -  Determine the response rate, disease free survival, and survival in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study of COL-3. Patients are stratified by&#xD;
      anticonvulsant (anticonvulsants that cause induction of CYP450 vs anticonvulsants that cause&#xD;
      modest or no induction of CYP450 or no anticonvulsant).&#xD;
&#xD;
        -  Phase I: Patients receive oral COL-3 daily. Treatment repeats every 4 weeks in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of COL-3 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive oral COL-3 daily at the MTD from the phase I portion of this&#xD;
           study.&#xD;
&#xD;
      Patients are followed every 2 months until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-18 patients will be accrued for phase I of the study and a&#xD;
      total of 35 patients will be accrued for phase II of the study at a rate of 3 patients per&#xD;
      month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>incyclinide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven high grade glioma that is progressive or recurrent following&#xD;
             radiotherapy or chemotherapy&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
          -  Prior low grade glioma that has progressed to high grade glioma following radiotherapy&#xD;
             and/or chemotherapy allowed&#xD;
&#xD;
          -  Measurable disease by MRI or CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT or SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction, stroke, or congestive heart failure within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
&#xD;
          -  No serious active infection or medical illness that would preclude compliance&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of gastrointestinal disorders that would interfere with absorption of study&#xD;
             drug&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ of the cervix or breast, or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No hypersensitivity to tetracyclines or its derivatives&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior large field radiotherapy (greater than 20% of total bone marrow)&#xD;
&#xD;
          -  At least 3 months since other prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior major upper gastrointestinal surgery&#xD;
&#xD;
          -  At least 14 days since other prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No prolonged sun exposure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Z. New, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. J Neurooncol. 2011 Nov;105(2):375-81. doi: 10.1007/s11060-011-0602-9. Epub 2011 May 6.</citation>
    <PMID>21547395</PMID>
  </results_reference>
  <verification_date>May 2003</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

